The DOI matches its Crossref record; 238 of the 239 references it cites were found in a registry or an index.
Anaemia in kidney disease: harnessing hypoxia responses for therapy
Open accessAbstract
Improved understanding of the oxygen-dependent regulation of erythropoiesis has provided new insights into the pathogenesis of anaemia associated with renal failure and has led to the development of novel therapeutic agents for its treatment. Hypoxia-inducible factor (HIF)-2 is a key regulator of erythropoiesis and iron metabolism. HIF-2 is activated by hypoxic conditions and controls the production of erythropoietin by renal peritubular interstitial fibroblast-like cells and hepatocytes. In anaemia associated with renal disease, erythropoiesis is suppressed due to inadequate erythropoietin production in the kidney, inflammation and iron deficiency; however, pharmacologic agents that activate the HIF axis could provide a physiologic approach to the treatment of renal anaemia by mimicking hypoxia responses that coordinate erythropoiesis with iron metabolism. This Review discusses the functional inter-relationships between erythropoietin, iron and inflammatory mediators under physiologic conditions and in relation to the pathogenesis of renal anaemia, as well as recent insights into the molecular and cellular basis of erythropoietin production in the kidney. It furthermore provides a detailed overview of current clinical experience with pharmacologic activators of HIF signalling as a novel comprehensive and physiologic approach to the treatment of anaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, upregulation of TNF family member proteins in nursing macrophages as well as maturing erythroblasts inhibits their differentiation even further and induces extrinsic apoptosis.31”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Research works printed but not linked: 12
- Yoon, D. et al. HIF-1α-deficiency results in dysregulated EPO signaling and iron homeostasis in mouse development. J. Biol. Chem. 281, 25703–25711 (2006). · DOI
- Klaus, S., Langsetmo, I., Neff, T., Lin, A. & Liu, D. beneficial pharmacodynamic effects resulting from 'complete erythropoiesis' induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592 [abstract]. J. Am. Soc. Nephrol. 19, 524A (2008).
- Besarab, A., Szczech, L., Yu, K. H. P. & Neff, N. B. Impact of iron regimen on iron indices and hepcidin during roxadustat anemia correction in incident dialysis patients [abstract]. J. Am. Soc. Nephrol. 25, 304A (2014).
- Frohna, P. A. et al. Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in subjects with CKD anemia [abstract]. J. Am. Soc. Nephrol. 18, 763A (2007).
- Provenzano, R. et al. FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis (HD) patients: phase 2 comparison with epoetin alfa [abstract]. J. Am. Soc. Nephrol. 23, 428A (2012).
- Brigandi, R. A. et al. The prolyl hydroxylase inhibitor, GSK1278863A, induced EPO in vitro and efficient erythropoiesis leading to increased hemoglobin in vivo [abstract]. J. Am. Soc. Nephrol. 21, 722A (2010).
- Brigandi, R. A. et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract]. J. Am. Soc. Nephrol. 23, 662A (2012).
- Shalwitz, R., Hartman, C., Flinn, C., Shalwitz, I. & Logan, D. K. AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults [abstract]. J. Am. Soc. Nephrol. 22, 45A (2011).
- Hartman, C. et al. AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia [abstract]. J. Am. Soc. Nephrol. 22, 435A (2011).
- Shalwitz, R. et al. AKB-6548: A new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels [abstract]. J. Am. Soc. Nephrol. 23, 56A (2012).
- Hartman, C. S. et al. Phase 2 study of AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD). akebia.com [online] , (2014).
- Boettcher, M.-F. et al. First-in-man Study with BAY 85–3934—a new oral selective HIF-PH inhibitor for the treatment of renal anemia. J. Am. Soc. Nephrol. 24, 347A (2013).
Cited by
Sorted by citations
The effect of HIF on metabolism and immunity
Taylor, C. T., & Scholz, C. C. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00587-8 · Cited by 517
Metalloimmunology: The metal ion-controlled immunity
Wang, C., Zhang, R., Wei, X., Lv, M., & Jiang, Z. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.11.007 · Cited by 302
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 282
Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets
Zhao, Y., Xiong, W., Li, C., Zhao, R., Lu, H., Song, S., Zhou, Y., Hu, Y., Shi, B., & Ge, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01652-9 · Cited by 269
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
Singh, A. K., Carroll, K., Perkovic, V., Solomon, S. D., Jha, V., Johansen, K. L., Lópes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113379 · Cited by 256
Metadata
- Authors
- Koury, M. J., & Haase, V. H.
- Affiliations
- Vanderbilt University Medical Center (US)
- Corresponding author
- Haase, Volker H.
- Venue
- Nature Reviews Nephrology
- Published
- 2015-06-09
- Volume
- 11
- Issue
- 7
- Pages
- 394-410
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- PMC
- PMC4497972
- OpenAlex
- W1893364029
- Cited by
- 313
- References
- 239
- Citations by year
- 2026: 20 · 2025: 28 · 2024: 26 · 2023: 39 · 2022: 45 · 2021: 36 · 2020: 31 · 2019: 20 · 2018: 22 · 2017: 20 · 2016: 20 · 2015: 5
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Nephrology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 BX002348)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080821, R01DK101791, R01DK081646)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- anemia of chronic kidney disease, erythropoiesis, erythropoietin, hypoxia-inducible factor, HIF-2, iron metabolism, inflammation, iron deficiency, renal failure, hepatocytes, oxygen sensing
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Anemia, Erythropoiesis, Humans, Signal Transduction, Cell Hypoxia, Renal Insufficiency, Chronic, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
